Nascent Biotech (Nascent Biotech) Change In Working Capital : $0.18 Mil (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Nascent Biotech Change In Working Capital?

Nascent Biotech's change in working capital for the quarter that ended in Dec. 2023 was $-0.06 Mil.

Nascent Biotech's change in working capital for the fiscal year that ended in Mar. 2023 was $-0.32 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Nascent Biotech Change In Working Capital Historical Data

The historical data trend for Nascent Biotech's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nascent Biotech Change In Working Capital Chart

Nascent Biotech Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Change In Working Capital

Get a 7-Day Free Trial

0.41

1.82

-0.10

0.91

-0.32

Nascent Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-0.36	0.05	0.23	-0.05	-0.06

Nascent Biotech Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.18 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Nascent Biotech Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Nascent Biotech's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Nascent Biotech (Nascent Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nascent Biotech Inc (OTCPK:NBIO) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408

Website

https://www.nascentbiotech.com

Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is actively engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.

Executives

Lowell Thomas Holden	director, officer: CFO	631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Sean Carrick	director, officer: President	631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Brandon Price	director, officer: Senior VP Business Development	6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121
Douglas John Karas	director	631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Mark Glassy	director, officer: CEO	6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121